Law360, New York (September 28, 2009) -- Abbott Laboratories plans to buy the pharmaceutical business of Belgium's Solvay Group for $6.6 billion in cash in a move to expand its presence in key emerging markets and diversify its drug portfolio.
The Illinois-based drugmaker said Monday that the acquisition would add more than $3 billion in annual sales and position it in high-growth markets in Eastern Europe and Asia. It will...
